Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9
Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $10 to $9.
Stocks · News reference
AdaptHealth Lowers FY2026 Sales Guidance from $3.450B-$3.520B to $2.850B-$2.890B vs $3.488B Est
AdaptHealth (NASDAQ:AHCO) lowers FY2026 sales outlook from $3.450 billion-$3.520 billion to $2.850 billion-$2.890 billion vs $3.488 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AdaptHealth shares are trading lower. The company appointed Harriss T. Currie as its Chief Financial Officer.
AdaptHealth Corp. Appoints Harriss T. Currie CFO, Effective Sept. 9, Succeeding Jason Clemens
UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.